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ABSTRACT: This paper examines the opportunities and challenges facing the pharmaceutical industry in moving to a primarily “continuous
processing”-based supply chain. The current predominantly “large batch” and centralized manufacturing system designed for the “block-
buster” drug has driven a slow-paced, inventory heavy operating model that is increasingly regarded as inflexible and unsustainable. Indeed,
new markets and the rapidly evolving technology landscape will drive more product variety, shorter product life-cycles, and smaller drug
volumes, which will exacerbate an already unsustainable economic model. Future supply chains will be required to enhance affordability
and availability for patients and healthcare providers alike despite the increased product complexity. In this more challenging supply
scenario, we examine the potential for a more pull driven, near real-time demand-based supply chain, utilizing continuous processing
where appropriate as a key element of a more “flow-through” operating model. In this discussion paper on future supply chain models
underpinned by developments in the continuous manufacture of pharmaceuticals, we have set out;
 The significant opportunities to moving to a supply chain flow-through operating model, with substantial opportunities in inventory
reduction, lead-time to patient, and radically different product assurance/stability regimes.
 Scenarios for decentralized production models producing a greater variety of products with enhanced volume flexibility.
 Production, supply, and value chain footprints that are radically different from today’s monolithic and centralized batch manufacturing
operations.
 Clinical trial and drug product development cost savings that support more rapid scale-up and market entry models with early
involvement of SC designers within New Product Development.
 The major supply chain and industrial transformational challenges that need to be addressed.
The paper recognizes that although current batch operational performance in pharma is far from optimal and not necessarily an appropriate
end-state benchmark for batch technology, the adoption of continuous supply chain operating models underpinned by continuous produc-
tion processing, as full or hybrid solutions in selected product supply chains, can support industry transformations to deliver right-first-time
quality at substantially lower inventory profiles. C© 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals,
Inc. and the American Pharmacists Association J Pharm Sci 104:840–849, 2015
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INTRODUCTION
The supply chain structure of the pharmaceutical industry
in terms of in-bound material supply, production footprint in
active processing and drug product manufacture, and down-
stream supply chain operations has not changed for decades.
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Despite healthy product margins and progressive improve-
ments in production process control and consequent produc-
tivity, the pharmaceutical industry when compared with other
process industries, operational performance levels are well be-
low process-industry norms on right-first-time quality, inven-
tory, and service levels. Structural changes to pricing models
may, in the future, also challenge this strong margin position,
as healthcare providers move to a manufacturing-cost-based
pricing model rather than the “value”-driven pricing arrange-
ments of today.
In terms of quality and the repeatability of manufacturing
processes, most pharmaceutical firms operate at levels of be-
tween 3 and 4F in termsmanufacturing right-first-time, costing
the global industry some $20 bn annually.
The current predominantly batch and centralized manufac-
turing model has resulted in product supply chains, which
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typically are between 1 and 2 years in length, with a huge
associated cost of inventory. The manufacturing assets that
most “big pharma” companies have for product manufacture
are suited to blockbuster supply, relying on large-scale cen-
tralized batch manufacturing plants, located predominantly in
developed countries. Current trends in the industry suggest
that smaller, more niche volume products will become the
norm with fewer blockbusters, within a market demand con-
text where globalization will require the ability to supply mul-
tiple geographically dispersed locations, collectively represent-
ing a more fragmented product portfolio. It is against this back-
ground that we seek, in this paper, to look at the impact of con-
tinuous manufacturing on the supply chain. In this context, we
go beyond the simple “batch” or “continuous” production process
technology choice, but consider how we might migrate supply
chains from a “batch” campaign mind-set, to a continuous ma-
terial flow model, utilizing continuous production processing
technologies where appropriate.
The paper considers how a change to continuous processing
might transform the industry to a more efficient and adap-
tive manufacturing supply chain that is being increasingly
demanded by institutional payers leading to benefits to end-
user patients. This is becoming all the more necessary for the
industry as new technologies and affordability challenges re-
quire multiple supply chain models that can deliver the drug
products of the future. The paper is structured as follows; iden-
tifying the scale of the opportunity, setting a vision for future
pharmaceutical supply chains and the business models that
this future contextmay involve, how these future networksmay
be designed, and the transformation challenges that need to be
overcome to realize the potential of continuous manufacture. In
this transformation context, the dynamic capabilities required
to transform the industry will be discussed and how both risk
and resilience will feature in the design of future supply chain
models.
SCALING THE OPPORTUNITY
In this section, we consider “What might the benefits of more
flexible, responsive continuous manufacturing-based end-to-
end (E2E) supply and innovation chains bring to the health-
care/pharmaceutical manufacturing sector?”
In our analysis of current E2E supply chains, we observe the
following potential opportunities from moving to continuous
process manufacturing:
i. Greater product and volume flexibility enabling multi-
ple supply chain models, more tailored to specific market
needs
ii. Significant inventory reduction opportunities through a
more responsive E2E SC (Supply Chain)
iii. Improved quality
iv. Rapid scale-up post clinical trials, perhaps redefining the
nature of clinical trials and subsequent commercial pro-
duction
v. Reduction in the management burden and overhead
structural costs they generate in the in the current supply
chain paradigm where multiple human to human hand-
offs are required to deliver product to patients
These five themes are further developed below, outlining
where the opportunity sits.
Greater Product and Volume Flexibility Enabling Multiple Supply
Chain Models, More Tailored to Specific Market Needs
It is now generally accepted that the pharmaceutical industry is
progressivelymoving away from the large volume “blockbuster”
drug production model and requires future production and sup-
ply chain models that can deliver significantly greater product
variety and volume flexibility. Indeed, this may involve product
delivery models developed or tailored to serve relatively niche
markets where patient populations are significantly smaller
than today’s norms. This, together with advances in stratified
and personalized medicines, will require levels of product cus-
tomization that make the batch centric production models of to-
day incapable of economically supplying these product varieties
(SKUs) at the smaller volumes required, and at the speed in-
creasingly demanded by end-users (patients and payers) with-
out the costly “buffer” of huge inventory.
The potential opportunities for “continuous processing” cen-
tric manufacturing supply chains include:
 New capabilities for firms to meet as yet unmet patient
needs, by developing capabilities to supply niche markets
that are currently uneconomical to serve because of the
small product volumes linked to specific patient popula-
tions.
 The volume flexibility afforded by continuous processing,
unconstrained by batch size, has major implications for
materials requirements and inventory, shortening dra-
matically the shelf-life of products that are often deter-
mined by minimum batch volumes.
 Better adaption to market supply and country versions:
variety of small markets (in terms of units produced, not
value) can drive a substantial accumulated volume. Im-
pact of individualized medicine can require a variety of
strengths that need to be produced, each as multiple coun-
try versions. In the batch world of today, this is difficult to
handle and negatively impacts on the Cost of Goods Sold,
inventory and shelf life requirements, as well as opera-
tional costs linked to increased complexity.
 Late customization and deferment models is another al-
ternative supply scenario, where final product definition
is achieved in-market within a distributed and geograph-
ically dispersed “final stage” manufacturing activity; in
this scenario, both upstream and downstream stages may
preferentially support continuous process technologies
that support “material flow” supply dynamics as opposed
to the current “batch” campaign model.
Within medium-to-large volume-scale manufacture, two key
questions emerge; the volume-scale where the transition from
batch to continuous becomes attractive, and whether the de-
sired volume flexibility may be achieved by various combina-
tions of batch and continuous processing. As continuous man-
ufacturing overcomes the discretization of batch sizes, it opens
up a range of volume options not otherwise possible. Further-
more, the development of post-dosing manufacturing capabil-
ities might afford further levels of late-customization when
applied to a common base product. If the latter is made con-
tinuously, the volume options for “minimum order quantities,”
a key criterion in supply chain design, become potentially un-
constrained.
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One potential application area is in supporting patient “dose
flexibility.” Whereas dose flexibility is already a reality in
injectable products, oral liquids, and semisolids, where the
patient is provided this flexibility, this may also be deliver-
able in discrete dose formats. For example, liquid forms pro-
duced in continuous mode, can potentially provide varying
formulations, process controlled to conform to specification. Al-
ternative technologies would be required for solid-dose forms,
such as additive production process models, ink-jet styled dose
control strategies, or novel “multi-dose” pack-formats and pack-
devices to deliver this dose flexibility functionality.
Late product customization, integrated with individualized
pack labeling, will be fundamental in supporting potential de-
velopments in individualized and personalized medicines. The
availability of faster and more flexible supply chains, as en-
abled by continuous processing, may also enable products and
dosage forms that inherently have shorter shelf lives.
Significant Inventory Reduction with a More Responsive E2E SC
The opportunities for a significant reduction in inventory
through continuous processing results from chemical pro-
cessing models offering reduced process steps and process
equipment that provides significant volume flexibility. This po-
tentially leads to substantial reductions in inventory which in-
turn enable:
 Moving to more of a “demand-driven” replenishment
model rather than the current long-term forecasting ap-
proaches with wider opportunities for manufacturing and
supply chain integration.
 The ability to operate on substantially shorter lead times
for product replenishment by significantly reducing inter-
mediate and finished goods stock levels.
 Consideration of chemical routes involving short-lived un-
stable intermediates within continuous manufacturing,
normally avoided in batch-chemistry, opening up alterna-
tive synthesis routes.
For these benefits to be effectively realized, the industry will
need to confirm the expected improvement in supply chain ro-
bustness and resilience ensuring complete confidence in the
supply chain delivering medicines to patients.
Improved Quality
Continuous processing can lead to substantially less rework,
assuming rapid start-up to steady state and that recycling
is routinely possible within agreed operating and regulatory
frameworks. As consistency is one of the hallmarks of continu-
ous processing, a well-designed and effectively run continuous
process can deliver a highly consistent product, leading to lower
variance and more reliable performance.
Continuous processing has, among other aspects, one funda-
mental differentiator from batch processes, which can have a
significant impact on the supply scenario. This aspect is process
control and the capability of enforcing process conditions at a
micro-level, which has a fundamental impact on development
processes, on quality and on supply.
Batch processes, for example, operate under the paradigm
that the totality of material is transformed in a reactor of some
sort, which holds the totality of material all at once. This makes
the reactor size dependent on the desired batch size. Reactor
size, however, drives the enforceability of process conditions of
the entirety of material on a micro-level. An illustration of this
is in an exothermic chemical reaction where heat management
is critical to controlling the reaction. The heat generation is
endogenous to the material and the heat control can only be
obtained by cooling the walls of the reactor. Temperature is de-
pendent on the distance of the point of interest to the wall. The
larger that distance, the smaller the impact of the wall temper-
ature, in our case, the cooling effect on the reactive conditions,
such that local overheating is a real possibility, as even with the
best temperature control in the reactor wall, the freedom of the
reaction to exhibit local overheating (that is not even noticed)
is high.
Similar examples exist for other processes, which may also
have complex numerical scenarios involved, aka nonlinearities
in material laws and heat flow or property propagation in gen-
eral terms. Examples include batch crystallizers, wet granula-
tion in shearmixers (high or low), including the fluid bed drying
of tableting processes, as the special distribution of properties
within a single tablet is not always uniform. In summary, the
larger the reactor is (or shall we better say the process equip-
ment to describe in an abstract way everything from a chemical
reactor to a powder handling system), the less control we have
over the real conditions that transform the material. Conse-
quences of that statement are among others that the quality of
the transformation is only loosely controlled, and a robust or in
other words forgiving product or formulation is needed to limit
the impact of this. Again in our exothermic reaction example
with poor control at the micro-level of reactive conditions like
temperature and mixing, local overheating may occur and even
degrade the product through a deteriorating follower reaction
or decomposition. In the batch world, these by-products will be
diluted into the entire batch and will raise impurities. Similar
effects can be named for almost any other unit operation: in
wet granulation local over granulation would come to mind, in
tablet formation capping as a consequence of inhomogeneity of
process conditions and so on, the list is long. So, in other words,
a different scale of unit operation has a fairly high chance of
quality attributes being scale dependent. One can even drill
this down to a tablet size being the determining factor for the
last “material transformation” in the pharmaceutical delivery
chain, the dissolution in the patient’s stomach. The consistency
potential of continuous processing is thus significant both in
terms of quality but also as set out below the opportunities for
more rapid scale-up.
Rapid Scale-Up Post Clinical Trials
In terms of the challenges in commercial scale-up of continuous
processes, once themanufacturing process has been established
within the clinical trial regime, these are widely recognized as
being significantly smaller and less expensive than for tradi-
tional batch processes.
The cost of bringing products to registration can be signifi-
cantly reduced when using continuous manufacturing for the
design of experiments (DoE) during development to support a
quality-by-design (QbD) filing. By way of exemplification, GSK
have demonstrated significant reduction in scale-up time and
cost during development by switching from batch to continuous
granulation.1 When a product transfers to commercial manu-
facture, it is anticipated that this will achieve reductions in
operating costs, work in progress, and footprint. This switch
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from batch to continuous granulation also provided evidence
of significantly reduced variance in the size distribution of the
granules. There are also potentially reduced material require-
ments for scale up in continuous processing trails. In a batch-
based operation, the scale is defined by the size of the process
equipment that is used. It defines the amount ofmaterial that is
exposed to a homogeneous application of processing conditions.
Any variation of processing conditions requires the production
of this quantity of material at the given set-point. This mul-
tiplies the material consumption per set-point with the batch
size and hence leads to huge material consumption to prove the
validity of different set-points of the processes. In continuous
processing, the variation of set-points can take place “on the fly”
and hence allows a much faster set-point screening. It practi-
cally replaces the minimum amount of material per processing
condition from the batch defined amount to an amount that is
given by the transient time it takes to change from one set-point
to another. These can be significantly smaller in a continuous
processing setting and hence the amount of materials required
for an array of set-points can be substantially reduced. This can
be seen as an easier and less costly scale-up model.
A specific example of reduced material requirements for
scale-up is in the quantity of API(Active Pharmaceutical In-
gredient) required to fully develop and scale up to commercial
scale. In a batch process, quantities are typically not available
at the phase II stage of development. Performing multivari-
able factorial DoE (a key component of QbD development) us-
ing large-scale batch processes is time consuming because each
data point in a multi-step process that could take several days
or weeks to generate. In contrast, a comprehensive DoE with
multiple data points could be performed in less than a day with
continuous manufacturing.
Reduction in Management Overhead Costs
As discussed earlier, significant managerial costs, often “hid-
den” in company manufacturing or supply chain overheads,
are driven by the managerial resources required to operate the
supply of products through the manufacturing supply chain. A
more continuous flow operating model would require system-
ized linkages across production and supply operations, mini-
mizing human to human hand-offs, and driving the need for
better demand signal detection through the E2E supply chain.
Currently, these overheads “allocated” to products may equate
to around 50% of the product cost, and although constitute a
multitude of cost factors, are primarily linked to the combi-
nation of expensive and under-utilized assets and associated
depreciation charges, but also the management costs involved
in the oversight of these complex interactions.
In quantifying the opportunity, Table 1 provides an assess-
ment of the potential scale of the opportunities across the theme
areas that can be targeted over the medium term.
The potential benefits longer term can be even greater than
those set out above but recognize the transformation journey
is unlikely to be realized quickly because of the factors set out
in later sections in this paper. Indeed, current industry perfor-
mance does not represent an optimized batch model—far from
it, and some observers will question whether an industry that
is unable to run what many would regard as simpler batch
processes effectively, can deliver efficient continuous manufac-
turing processes. However, a key difference is that continuous
processes impose disciplines that are optional in a batch model.
CONTEXT/FUTURE VISION
Here, we consider how might the healthcare/pharmaceutical
industrial ecosystem evolve in a predominant continuous man-
ufacturing innovation and supply model in terms of changes to
industry structure, adoption of enabling technologies, and the
provision of new products and services to smaller patient group
populations? Potential future developments within themedium
term timeframe include:
i. Patient (rather than health provider) centric supply
chains that support multiple value and supply chain con-
figurations, coexisting and providing different, often more
localized and dynamic replenishment models.
ii. Simplified supply chain operations with less managerial
oversight and regulatory sanction.
iii. More responsive production and distribution models that
can support rapid replenishment driven by the emergence
of patient management diagnostics and “Apps,” medical
devices, and supply chain integrating IT systems.
iv. Reduced capex and operating costs, and volume flexibil-
ity, afforded by continuous processing supports more geo-
graphically distributed production and supply networks,
closer to patient demand.
v. Process-control-based quality and regulatory assurance
becoming established mechanisms, supported by ad-
vances in Process Analytical Technologies (PAT) that pro-
vide real-time data on product and process consistency
during production, and used to quality assure product di-
rect into the supply chain.
vi. Easier supply to smaller patient groups (by strength,
by country) including earlier access to commercial scale
materials for patients, as scale-up requirements be-
come significantly less onerous. The reduced development
timelines can increase the profitable supply time for in-
novators, allowing more development resources for the
overall enterprise (assuming a supportive regulatory en-
vironment).
vii. More localization, enabling more dynamic closed loop
control, with control parameters set upstream based on
downstream measurements.
In terms of future scenarios, we might imagine the progres-
sive emergence of cheap robotics and microprocessor control
as well as advanced, but cheap, sensor systems supporting new
models whereby complexmolecules and bio-pharms are synthe-
Table 1. Scaling the Potential Opportunities Across the End-to End
Supply Chain
End-to-End Supply Chain Opportunity
Reducing inventory within primes from >200 days to <70 days
Manufacturing—cost of quality, achieve >5F, right-first-time
1–2 years inventory days of supply—opportunity to reduce up to 50%
Reduce cycle time by half (starting materials to packed product)
Reduce drug development cost, currently at $1.15 bn/drug,2 by 10%
(cost to market)
Enhance flexibility and service to patients, improving both patient
service and compliance through more demand driven responsive
supply chains
Reduction in management overheads, reducing the manual
interactions in the oversight of batch-campaign operating models,
through enhanced flow-through supply concepts
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sized on small modular platforms, and numbered up to scale (as
required). The decentralization of manufacturing that would
occur would be unprecedented in the chemicals industry.
Another example of future implementation paths is the use
of hybrid 3D printing systems to produce configurable flow reac-
tors with sensing, actuation, reaction processing, purification,
and so on. 3D printing is a process where objects can be fabri-
cated layer by layer, or part by part, allowing computer design
and easy customization of architectures. 3D printers come in
several flavors, as well as high-end commercial systems and af-
fordable, open source, user customizable devices. For instance,
Cronin et al. have shown it is possible, using open-source 3D
printers, to “hack” plastic laboratory ware. However, the devel-
opment of this “hackware” is allowing the development of hy-
brid devices where the 3D printer is used not only to construct
a test tube for a chemical reaction, but also deploy/pump the
chemicals into the test tube for the reaction and also customize
the test tube to allow certain reactions to happen in different
ways. This could even be extended to biologics by printing bio-
reactors. The 3D printer acts in two ways. Firstly, it can be
used to fabricate the plastic-ware, or “reactionware” (the “flow
system” in which the chemistry is carried out), and secondly we
can use the printer as a robot to move chemicals around to do
chemical reactions. The 3D model can particularly support the
deferment and late customization supply models within sec-
ondary processing, by allowing near-to-end market final pro-
cessing and customization.
The potential realization of the “modular” chemical factory
would require a new set of standards allowing modular inter-
change from a physical, chemical, electronic, and software point
of view. The natural consequence of this could enable the re-
tasking of the “factory” to produce new chemicals or drugs on-
demand with zero extra capital cost or investment. This vision
requires a radical new integration of chemical systems and syn-
thetic methodologies developed within this new paradigm. The
ultimate outcomewould be the development of largely software-
only manufacturing work-flows whereby the physical system
could be reconfigured electronically. (This is similar to peptide
or DNA synthesis today but DNA synthesis is an order of mag-
nitude more reliable than peptide synthesis due to the combi-
natorial problem of conditions for coupling and deprotection as
well as purification.)
Again the move to more niche products, possibly with lo-
cal supply will be enabled by smaller, flexible manufacturing
operations. The cost of build when comparing with batch for
scale manufacturing plants is potentially reduced by >30%,
with physical footprints reduced by >25%, cost of operations
reduced by >30%; these modest quantifications of potential
benefits are based on successful continuous manufacturing ex-
amples already implemented.
At the personalized medicines level, personal “pill” fabri-
cation may have a rather novel application for the consumer.
We might imagine a patient that has complex medical issues
requiring multiple drugs with multiple dose variations over
time. Remembering to take the correct drugs at the correct
time is an increasing problem. The local use of “pill-printers”
that would simply combine pre-formulated version of the drugs
together in either a liquid or solid form using a liquid or pow-
der handling robot into a single dose. The “printer” would be
programmed with the prescription of the patient and the drugs
mixed together in a binder matrix and then formed into the
pill. This could have obvious benefits for the patient in terms of
adherence to treatment regimes, improving compliance espe-
cially for elderly patients with complex medical conditions.
Final delivery models to the patient could by-pass the cur-
rent specialist distribution and pharmacy network with di-
rect delivery models, already developed in prototype packag-
ing equipment packing halls, able to serve patients directly
with individually named product prescriptions, with multiple
products filled on the same line with accuracy levels exceeding
the manual checking undertaken within current “pharmacy”
models.
Experience from other industries suggest this type of trans-
formation to more flexible localized operations based on chang-
ing process technologies and more customized solutions is pos-
sible. Transformation examples with analogous comparisons
with sector level transformations in other industries include:
computer-assisted processing and control in aircraft, decentral-
ization of the printing industry, and transport.
Computer-Assisted Processing and Control in Aircraft
The E2E continuous processing supply chain will be per se
technically very complex, most likely more complex than the
current batch model. However, clever use of computerized pro-
cedures will enable a better management of these procedures.
An analogy with aircraft is that the Airbus A380 is more com-
plex to fly compared with a 1950s prop plane. However, modern
control systems can stabilize flight dynamics, navigate, and
control the system much better, such that crew can reliably fly
this plane and operate it more economically such that mass
tourism is now possible, whereas in the 1950s, it was a very
much a luxury. The inherent complexity in continuous process-
ing will drive adoption of computer-assisted processing, and
greater scrutiny in quality management. We can expect sig-
nificant benefits to arise from this intense computerization. In
chemical synthesis, the emphasis may be on liquid processes
instead of solid/liquid dispersions that are easier to control and
handle. The processes need to become simpler and more robust
in hardware and the higher demand for control can be accom-
modated in software. This gives rise to a common, and highly
compatible, hardware installation and greater impact on soft-
ware/control. Once accomplished, technical transfers can be as
simple as sending data.
Decentralization of the Printing Industry
The change in supply network structure in moving to continu-
ous processing can be seen as a bifurcation point, as although
technically more complex at a processing level compared with
the batch paradigm, there is substantial opportunity for sig-
nificant automation. A historic analogy illustrates this point.
Printing in Gutenberg’s time was a relatively simple process at
a technical level. Even in the 1970s, it remained a fairly simple
process albeit complicated by the addition of the mechanical
features of mass-production. The printing process as such was
still a simple shaping exercise of a stamp of some sort, inking
it somehow, and transferring that ink to a sheet of paper. To-
day’s laser printing is technically much more complex, but it
is universally available, even when consumers do not have the
slightest idea as to what is going on inside the printer itself.
The overall global consumption of paper has risen signifi-
cantly since decentralized printing became available, despite
the increased complexity of the technology. It is useful to note
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that the first laser printers in the 1970s were research institu-
tion type activities and yet are now a ubiquitous commodity.
In this example, complexity increases substantially in the
initial phase requiring technical specialization with production
capacity in centers of expertise. However, as the technologyma-
tures, production is progressively decentralized and requires
smaller footprints at each production site. Decentralization will
then drive supply chain topologies in different ways, as QA as-
pects are managed through in-field real-time data, or in the
case where intervention is needed, the “cloud”-based operator
electronically sends the necessary (software) upgrade. Today,
the printing industry is highly decentralized, with printers
now regarded as consumer goods. The flexibility of the print-
on-demand decentralized model has outperformed the per se
much faster high-speed printing technology of the traditional
print-shop. A similar evolution, of decentralized production
with software-based QA and upgrade interventions may also
evolve within the continuous manufacturing model.
Transport
In commercial road transport, vehicles are able to take a va-
riety of routes and select multiple stopping points. Vehicles
themselves can have many operating states; traveling at speed,
stationary with engine running, stationary with engine turned
off, and so on, providing flexibility on delivery route to be taken
and the ability to adjust operating costs throughout the jour-
ney. In an airplane however, one must operate at a minimum
speed, and after take-off typically fly at a predetermined speed
and route. Problems during the flight’s trajectory must be cor-
rected during motion with limited opportunities to “take-stock”
and make unplanned stops. Both road and air transport modes
offer opportunities and limitations, and selecting the correct
mode of transport, or combinations of the two modes is deter-
mined by the context and flexibility required. There is no doubt
that different transport requirements, in terms of distance to
be traveled and number of drop-points will favor air or road
transport in different ways, and a smart combination of both
approaches will best support a diverse supply landscape.
These future supply scenarios highlight how batch and con-
tinuous operating models have evolved in other industries.
These examples serve to demonstrate how decentralized and
highly controlled process technologies have influenced the evo-
lution of supply chain models in other industries and the mind-
set required to make such changes a reality.
CAPTURING VALUE ACROSS THE E2E SUPPLY CHAIN
In this section, we explore the potential new business mod-
els and value propositions that might emerge from a more in-
tegrated E2E continuous manufacturing-based supply chain
and whether the existing infrastructure meets the needs of the
changing product portfolio. Example developments to capture
value across the supply chain include:
 Emergence of products supported by Medical Diagnostic
Devices enable the capturing of product demand require-
ments directly between patient and drug provider.3 In a
highly networked scenario, the supply chains would op-
erate as reconfigurable and adaptive networks that are
IT enabled responding to demand fluctuations, linked to
remote Patient Diagnostic and Management Systems.
 Technology Convergence; between and within medical
technologies that support new (more integrated and pa-
tient centric) product and product-service solutions that
are more effectively delivered through multiple supply
chain models including continuous processing-based sup-
ply.
 The potential development of personalized packs de-
scribed earlier, through technologies that support late
customization of products, and novel packaging solutions
that facilitate patient compliance and adherence, such as
multi-product personalized pack-solutions.
 Decentralized supply models; current batch practice to de-
velop sophisticated scale-up scenarios often involves de-
veloping forgiving materials or reactions and as a last
resort to widen the quality specs, and locking them as
late in the development process as possible. Continuous
processes however slice the process conditions along a
time axis and hence allowmuch smaller distances between
process conditions as enforced at the boundary of our con-
trollable space and the entirety of the material. This leads
to the need to not only know better about the process,
but ability to control at a micro level with consequences
for improved quality. The other consequence is that the
equipment as such is never holding the entirety of ma-
terial all at once and typically is not only from a reactor
room perspective but also from a footprint perspective sig-
nificantly smaller. Consequently, the process equipment
is smaller, the development process is technically more
complex but gives better understanding sooner in the pro-
cess and hence opens the path to muchmore decentralized
supplies for commercial supply scenarios (but also for late
phase development scenarios where the supply aspects
becomes inherently more important over the “create” as-
pects of R&D). Whereas for a classical batch regime, this
typically involves a monolithic supply center, the contin-
uous paradigm opens the opportunity of developing the
fundamental process understanding earlier in R&D. The
quantities of materials needed to develop a higher level
of process understanding is reduced and then the scaling
becomes much less of an issue, if there is a scaling needed
at all. Procedurally speaking, the technical transfer into
a continuous supply center can take place sooner in the
technical development timeline, or if the responsibility is
transferred by the regulatory status of the project (“R&D
hands over to TechOps at Phase III supply manufacture”)
in other words, with fewer development efforts.
 Risk Transfer and Commercial scale-up; if the product vol-
umes are significantly smaller as compared with a block-
buster scenario, then the phase III supply and the launch
supply have a chance to be on the same process equip-
ment and even a sustainable commercial supply can be
organized in a significantly smaller decentralized supply
scenario avoiding risky technical transfers. Risk reduction
is plausible as the amount of process enforceability at a
micro-level is significantly better giving fewer degrees of
freedom for things to gowrong upon site transfers. It needs
to be understood though that the technical (engineering)
complexities of a continuous production are significantly
higher in the design and operational phase.
 Reconfigurability of assets: although continuous process
engineering and science will drive more complex pro-
cesses, they will provide opportunities for better process
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control, better quality, and smaller footprints, leading to
smaller supply centers and eventually faster transfers
into them. Taken one step further, the localization of this
value generation allows amuch greater flexibility in terms
of physical assets as a smaller plant is easier to relocate,
and the driving factor becomes much more the availabil-
ity of human brain-power at these dispersed locations to
manage the inherent process complexities.
Existing infrastructure is unlikely to support the needs
of the evolving portfolio and emerging supply models; fewer
blockbusters, more niche products, stratified/personalized
medicines. Nor is that infrastructure likely to be in the right
place with changes to markets, products, and scale. With the
emerging markets playing a bigger role in the future thought
needs to be given to how they are effectively supported and how
this might impact changing industry structure from both a ge-
ographical distribution perspective, and asset ownership with
contract manufacturing models providing specialist capability
and capacity. The potential of reduced inventories and work-in-
progress represents perhaps the greatest opportunity for value
creation with potential to take out up to 1 year of inventory
across the extended supply chain.
DESIGNING THE E2E SUPPLY CHAIN
Here, we consider the desirable future product, process, and
supply network configuration models in a highly continuous
manufacturing innovation and supply model. It is perhaps im-
portant to note that we envisage multiple supply chain models
with configuration scenarios that include:
 Geographically dispersed production networks, supported
by more repeatable continuous-based production pro-
cesses, and offering significant volume flexibility with a
flow-through demand driven supply dynamic, progres-
sively replacing the “batch campaign.” Unit operations
will involve fewer production steps that change produc-
tion dynamics from multi-stage multi-location to single
location processing.
 Multiple supply chain models that support different levels
of geographical reach, with, for example, centralized sup-
ply solutions feeding late customized/consolidation mod-
els; or alternatively dispersed supply models that support
local near-market replenishment models.
 Fragmentation of the downstream supply chain with new
“actors” emerging providing specialist services and oper-
ating within agreed operating models.
 Localization in small markets is enabled by small con-
tinuous lines; the “Factory in a box” is one scenario but
so are smaller more standard factory operations that are
substantially less capital, labor, and energy intensive pro-
viding more resource-efficient sustainable operations.
 Manufacturing “on-demand” with less inventory enabled
by continuous lines, which are very well controlled at
steady state—reducing the uncertainty of current man-
ufacturing and forecasting processes.
 Continuous processes that enable closer coupling of API
and Drug Product operations. However, the need for
buffers of intermediatematerials should not be wholly dis-
counted. From a quality perspective, control of particles
at API should enable more reproducible drug substance
manufacture.
 Looking to the future, 3D printing-based supply models
enabling local manufacture for a patient-specific drug as
part of future developments in personalized medicine.
The transformations will require changes to the roles of ex-
isting industry players supporting these more patient-centric
demand driven supply chains. From an equipment perspective,
improved sensor and control systems to match up to a plug
and play approach on a particular manufacturing site, poten-
tially rolled out to across multiple locations. In this scenario, a
number of small flexible factories controlled centrally in their
operation may support Intellectual Property control and qual-
ity assurance while having geographically dispersed physical
manufacture.
RESOLUTION ACTIVITIES (AND CHALLENGES)
A number of global initiatives have been commissioned to take
on elements of the transformation challenge. For example, in
technology development, programmes are already underway
that are required in continuous manufacturing. These include
a UK Centre for Continuous Manufacturing and Crystallisa-
tion (CMAC), a US-based Novartis-MIT Center for Continuous
Manufacturing, the US Centre for Structured Organic Particu-
late Systems (cSOPS), Ireland SSPC (Synthesis and Solid State
Pharmaceutical Centre), various European consortia, and sev-
eral prototype equipment developments (e.g., UK CMAC Re-
search Partnership Investment Fund). More recently, a new
initiative to developing an E2E Supply Chain “eco-system” that
considers technology developments (including continuous pro-
cessing developments) within new supply chain models and the
appropriate regulatory regimes required at an industry sector
level have been commissioned (UK ReMediES project). These
industry-research (and regulator engaged)-based consortia ini-
tiatives are enabling sector-wide “pre-competitive” collabora-
tions to support and accelerate transformations to continuous
processing.
A key challenge for these teams is in identifying specific
product groups where continuous process manufacturing is at-
tractive. Initial research suggests that we should not assume
immediately that a SC based on continuous is more flexible and
responsive, and that moving an existing product into a continu-
ous (drug product) systemmay require significant development
work. On the development side, we should require much less
API for DoEs, engineering runs and validation runs, which will
support experimentation where material cost or scarcity is an
issue. Another key feature of Continuous Manufacture is that
it converts the transformation processes from a strictly step-
wise and multiple unit operations-based approach into a world
of constant flow of energies and materials. This eliminates the
necessity to have holding points before and after each unit op-
eration and eliminates the requirement for the materials to
have the ability to survive the holding point without compro-
mising quality. An example is where unit operations are broken
up into different geographical locations, to take advantage of
duty and tax regimes requiring the shipping of intermediates;
these business models constrain the freedom of the process
designer and make certain routes impossible, which might oth-
erwise be feasible in continuous manufacturing. On the other
hand, in a continuous sequence of processes that are always
dynamic, there are limits to possibilities for rework. Also, there
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is no easy route to stopping a process mid-stream, make a deci-
sion, as it is always in flow. Mastered adequately a continuous
process offers unique benefits but is not the solution for all
cases.
TRANSFORMATION CHALLENGES
Finally, we explore the major transformational challenges (be-
havioral, technological, regulatory, etc.) that continuous-based
manufacturing and supply models need to overcome. Four key
areas are identified regarding transformation to continuous
processing, namely:
i. Fostering a multi-disciplinary approach across technical
and manufacturing disciplines, including requirement for
better connectivity between discovery, development, and
manufacturing organizations.
ii. Technology integration across Pharma and Bio-Pharma
supply chains including diagnostics to enable patient cen-
tric supply chains.
iii. Derisking investment decisions and overcoming barriers.
iv. The role of policy across pharma supply chains.
These are explored with recommendations for industry, sup-
ply chain practitioners, academia, and regulators and where
appropriate, comments from the literature included.
Fostering a Multi-Disciplinary Approach across Technical and
Manufacturing Disciplines
Changing the Mind-Set
Changing the mind-set of industrial and institutional profes-
sionals, such as regulators, manufacturers, and process engi-
neers, to continuous processing and a retraining of staff will be
essential for achieving substantial transformation. At a tech-
nical level, this will require developing better capabilities both
in continuous synthesis and in the design of continuous drug
product manufacture, right through to downstream pack and
distribute technologies that can accommodate product variety
and flexibility.
Transforming Control Regimes
Sampling and testing aliquots of material to confirm quality
and manual feedback loops in various Quality organization se-
tups will not be possible nor adequate in continuous manufac-
turing. If the continuous processing needs the process dynamics
to be controlled automatically, as in the flight dynamics of mod-
ern flight control systems, the oversight in the field will not
be the paper screening of Food and Drug Administration’s field
inspectors but the approval of the control system and the as-
surance that the operational parameters are as intended. The
quality evidence provided in today’s paradigm is either based on
manual or simple computerized systems because the integra-
tion across systems is according to discipline not according to
products. For example: an analytical LIMS system manages all
chromatographic data within an organization. The complexity
per data entry (meaning per sample) is simple, but because the
integration is vertical along all such procedures within an orga-
nization, the sheer amount of similar data is overwhelming and
here the complexity starts (operator, equipment tag, reagents,
injections, sample number, etc.). In the laser printer case, an
integrated Photodiode can measure the deposition density of
the toner in-line, its data is only used to control this particular
printer at the given optimal time-point and guarantees the opti-
mal quality of the printout. Occasional verification is sufficient
to verify proper function of all systems and the self-surveillance
of the system can help to manage operation.
Tackling Organizational Inertia
The current modalities within many large firms in established
industries, particularly in those that are highly regulated
and technology intense, has involved “committee-based” deci-
sion making, often through multi-layer matrix organizations.
It has been suggested that this has driven a risk avoidance
and tick-boxing culture at a functional level, which promotes
incremental innovation despite long product life cycles, at the
expense of genuine cross-functional radical innovation. Reg-
ulatory contexts inadvertently lock-in these behaviors and
preference to established processes. However, in some organiza-
tions, we are nowwitnessing the creation of “autonomousmulti-
functional teams,” with substantially more devolved responsi-
bilities, to drive more radical transformations—teams that are
given the resources, timeframes, and mandates to deliver. Al-
though these are relatively new developments, examples from
both the aerospace and pharmaceutical sectors, who both ex-
hibit similar organizational characteristics, partly driven by
their industry structures, product architectures, and regula-
tory frameworks, suggest the “continuous processing” models
will require such multi-functional teams to develop specific
supply chain models. These multi-functional teams have the
opportunity to enhance connectivity between discovery, devel-
opment, and manufacturing organizations, particularly impor-
tant in large pharma. In addressing these organizational silos,
which are often functional and discipline based, we can encour-
age the breakdown of unhealthy sub-cultures (that can promote
incrementalism and silo behaviors), to take on more challeng-
ing cross-functional targets. This will involve developing a new
crop of technically based leaders, workingwithin both their own
organizations and external parties. Reconstructing industrial
“systems” will involve new partnering models with external
players focused on delivery against system outcomes. Indus-
try evolution more broadly may result in refocusing industrial
activity of the main players on specific elements of the value
chain; restructuring activities on value adding activities, per-
haps involving mergers and acquisition of firms that operate
across the supply chain where vertical integration is critical to
product/service delivery.
Interestingly, as current processes and trends move to de-
mands for an ever growing granularity of control per individ-
ual control event, the increasing complexity of products and
technologies will challenge the existing approach of batch-lot
control with its technical limitations, driving firms and regu-
latory agencies to a system change for the next generation of
products. This change in paradigm emerges surprisingly per-
haps from the combination for more assurance within the con-
text of increasing complexity, requiring more “systems” cross-
functional approaches to quality assurance and new product
introduction.
The organizational issues raised here are further explored
in the white paper by Krumme et al.
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Technology Integration across Pharma/Bio-Pharma Supply Chains
Including Diagnostics to Enable Patient Centric Supply Chains
Integrated product and product-service replenishment models,
driven for example by remote diagnostics or near real-time
demand signals, will require technology advances that can
enable/drive more patient (or institutional user) centric sup-
ply/demand models, reducing the reliance on intermediaries.
The product categories, patient populations or therapy areas
where tightly coupled supply chains might emerge will inform
the technology requirements across the product-process-supply
domains. Key criteria will be product volume and variety, vol-
ume uncertainty and lead-time requirements.
The emergence of new supply models will require policy and
regulatory advances that support more direct supplies.
Within the process technology choices during various stages
of industry transition, the hybrid batch/continuous models that
might progressively support changemay be a key consideration
in the “road map” to continuous manufacturing and supply.
These industrial transition points will themselves have critical
dependencies on a number of new technologies, such as better
analytical systems, new catalysts, new enzymes, novel control
systems, and so on, which in their various combinations will be
required to drive success.
At the molecular level, these developments will not only re-
quire a rethinking of current molecular discovery to scale up
processes, but also require engineers, chemists, and software
designers to work together in new ways. Conceptually, organic
chemists often work out how to make their target molecule by
working backward and reducing the complex molecule to sim-
pler ones step by step on paper, only to reverse the process in
the laboratory and build the molecule up. An example of such
multi-disciplinary activity is the potential of molecular discov-
ery, scale-up, and crystallization—these processes are being pi-
oneered in the Cronin lab to try and develop this chemistry into
“reactionware.” This is not so different from the development
of continuous processes from batch to flow. The difference with
“reactionware” is that the scaling of the system is much easier
and faster because of the ability to rapidly prototype the flow
systems using plug and play plastic modules. Of course, we pro-
pose going several steps further and using standard modules
that can do advanced operations such as separations, crystal-
lizations, and forming composite or formulated products. If the
units are cheap, scale up via reactor numbering up is poten-
tially transformative in terms of cost, time, and configurability
and mobility.
Derisking Investment Decisions and Overcoming Barriers
Managing the uncertainty and risk of novel processing routes
in Clinical and Commercial supply chains will be critical within
any industry adoption of continuous technologies. This calls for
industry wide pre-competitive activities to derisk projects and
build industry capabilities together with institutional players
and regulators.
Another key requirement is lowering barriers to entry—
through shared facilities and infrastructure, PAT capability
advances at sector level that provide product-process quality
assurance, and the proactive development of appropriate regu-
latory contexts.
Any new technology carries opportunities and risks. In the
originator’s pharmaceutical business, the main risk is the
approval of the compound, driven by the success of the clin-
ical program and the convincing power of the dossier. For a
single compound, this is a complex function of a variety of fac-
tors, some of which are better manageable than others. The
performance and properties of the molecule on the receptor is
one element, the biopharmaceutical adequacy of the drug prod-
uct to the kinetic properties at the receptor and the route to
get there is the other and at the end of the day, the feasibility
and robustness of distinct process trains for a particular drug
product design is of the essence. The magnitude of the risks is
typically much larger on the clinical side for originators and
hence the focus on secondary risks needs to be minimized. This
can be accomplished by a variety of approaches using:
 Technology platforms that are applicable to multiple
projects
 New technologies only late in the clinical programs or as
life-cycle management tools
 New technologies in a dedicated spin-off that offers the
technology for the industry as a whole and hence spreads
the risks across multiple products and companies
To value the opportunity and risks adequately, one should
not solely consider the technology platform and the success of
a specific product or clinical performance, in fact they mostly
have nothing to do with each other, other than the fact that a
platform has been picked for a particular program. Instead, it
is essential to understand what a particular platform delivers
in terms of functionality, cost, timelines, and robustness, and
quantify those factors. For continuous processing, this reduces
the risk to the pure technical risk and other aspects that drive
in the long run the success of the process technology on its real
merits.
The Role of Policy and Regulatory Regimes across Pharma
Supply Chains
Societal expectations, in developed and emerging markets, will
increasingly demand more affordable and/or specialized prod-
ucts available to those who need them.
Institutional pressures on affordability and the demographic
impact on national health budgets are expected to drive more
efficient supply chains and business models that no longer tol-
erate the inventory buffers of today. However, the transition
to more efficient supply models will require institutional part-
nerships (government, regulators, and research bodies) with
technology and industrial players.
From a regulatory perspective, we anticipate process en-
gineering, analytical methods such as spectroscopy, and data
analysis and statistics become progressively more important.
Real time access to data and data analysis become the norm,
with large-scale sampling and dynamic control methods influ-
encing the regulatory paradigm.
CONCLUSIONS
In this discussion and review piece of industrial and academic
perspectives on the future supply chain models that might be
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underpinned by developments in the continuous manufacture
of pharmaceuticals, we have set out:
 The significant opportunities to moving to a continu-
ous manufacturing supply chain operating model, with
substantial opportunities in inventory reduction, lead-
time to patient, within radically different product assur-
ance/stability regimes.
 Scenarios for significant decentralized production
and supply models producing a greater variety of
differentiated products with greater volume flexibility
and opportunities for rapid scale-up post clinical trials.
 Production, supply, and value chain footprints that are
radically different from today’s monolithic and centralized
batch manufacturing operations.
 Clinical trial and drug product development cost savings
that support more rapid scale-up and market entry mod-
els, with early involvement of SC designers within New
Product Development.
 The major supply chain and industrial transformational
challenges that need to be addressed.
Although the potential benefits against current batch per-
formance benchmarks are significant, identifying the product
supply chains where benefits might be most attainable is com-
plex and the transformation journey far from straightforward,4
with future archetypes including hybrid batch-continuous
scenarios.5
Benchmark studies should also consider improvements to
current batch operations which operate far from optimal lev-
els. Indeed, some industry observers will question whether the
pharma sector can effectively implement these more techni-
cally complex continuous processing supply models,6,7 models
that require production to operate at near optimal levels “by-
design,” or whether this very requirement will in itself help
drive the efficiency improvements demanded by patients and
payers alike.
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